 |
 |
 |
|
 |
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
OPAXIO™ Studies in Ovarian CancerCTI and the Gynecologic Oncology Group (GOG) are presently evaluating OPAXIO as monthly maintenance in a phase III clinical trial in ovarian cancer patients who have achieved a complete response following standard first-line chemotherapy.Target enrollment for the trial, which includes a third paclitaxel arm to determine safety, is approximately 1,100 patients. The GOG has established the standards for treatment of ovarian and other gynecologic cancers in the United States and has a track record of conducting high quality clinical trials upon which product registration has been based. Ovarian cancer ranks fifth in cancer deaths among women in the United States. The American Cancer Society estimates that there will be about 21,650 new cases of ovarian cancer and 15,520 deaths in the United States during 2008. OPAXIO
Fact Sheet (226k PDF) Posted March 18, 2008
|
|
|||||||||||||||||||||||||||||||||||
|
|
|
|
